menu
    • menu
    [{"orgOrder":0,"company":"Henan Cancer Hospital","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Epirubicin Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Henan Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Henan Cancer Hospital \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Henan Cancer Hospital \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Peking University","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Epirubicin Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Peking University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Peking University \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Fudan University","sponsor":"Shanghai Zhongshan Hospital | Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Epirubicin Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase IV","graph3":"Fudan University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fudan University \/ Shanghai Zhongshan Hospital | Johnson & Johnson","highestDevelopmentStatusID":"11","companyTruncated":"Fudan University \/ Shanghai Zhongshan Hospital | Johnson & Johnson"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Epirubicin Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"GBG Forschungs GmbH","sponsor":"Bristol Myers Squibb | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Epirubicin Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"GBG Forschungs GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GBG Forschungs GmbH \/ Bristol Myers Squibb | Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"GBG Forschungs GmbH \/ Bristol Myers Squibb | Amgen Inc"},{"orgOrder":0,"company":"AIO-Studien-gGmbH","sponsor":"Amgen Inc | WiSP Wissenschaftlicher Service Pharma GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Epirubicin Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"AIO-Studien-gGmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIO-Studien-gGmbH \/ Amgen Inc | WiSP Wissenschaftlicher Service Pharma GmbH","highestDevelopmentStatusID":"8","companyTruncated":"AIO-Studien-gGmbH \/ Amgen Inc | WiSP Wissenschaftlicher Service Pharma GmbH"},{"orgOrder":0,"company":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Epirubicin Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie \/ Amgen Inc"},{"orgOrder":0,"company":"Jules Bordet Institute","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Epirubicin Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Jules Bordet Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jules Bordet Institute \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Jules Bordet Institute \/ Sanofi"},{"orgOrder":0,"company":"Lund University Hospital","sponsor":"Swedish Breast Cancer Group | Danish Breast Cancer Cooperative Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Epirubicin Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Lund University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lund University Hospital \/ Swedish Breast Cancer Group | Danish Breast Cancer Cooperative Group","highestDevelopmentStatusID":"10","companyTruncated":"Lund University Hospital \/ Swedish Breast Cancer Group | Danish Breast Cancer Cooperative Group"},{"orgOrder":0,"company":"West German Study Group","sponsor":"AGO Germany","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Epirubicin Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"West German Study Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"West German Study Group \/ AGO Germany","highestDevelopmentStatusID":"10","companyTruncated":"West German Study Group \/ AGO Germany"},{"orgOrder":0,"company":"West German Study Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Epirubicin Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"West German Study Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"West German Study Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"West German Study Group \/ Undisclosed"},{"orgOrder":0,"company":"Australasian Gastro-Intestinal Trials Group","sponsor":"National Health and Medical Research Council, Australia | Trans Tasman Radiation Oncology Group | European Organisation for Research and Treatment of Cancer | NCIC Clinical Trials Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Epirubicin Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Australasian Gastro-Intestinal Trials Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Australasian Gastro-Intestinal Trials Group \/ National Health and Medical Research Council, Australia | Trans Tasman Radiation Oncology Group | European Organisation for Research and Treatment of Cancer | NCIC Clinical Trials Group","highestDevelopmentStatusID":"9","companyTruncated":"Australasian Gastro-Intestinal Trials Group \/ National Health and Medical Research Council, Australia | Trans Tasman Radiation Oncology Group | European Organisation for Research and Treatment of Cancer | NCIC Clinical Trials Group"},{"orgOrder":0,"company":"OHSU Knight Cancer Institute","sponsor":"Bayer AG | Oregon Health and Science University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Epirubicin Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"OHSU Knight Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OHSU Knight Cancer Institute \/ Bayer AG | Oregon Health and Science University","highestDevelopmentStatusID":"8","companyTruncated":"OHSU Knight Cancer Institute \/ Bayer AG | Oregon Health and Science University"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Prestige BioPharma Pte Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Prestige BioPharma Pte Ltd \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Epirubicin Hydrochloride

    Menu

    Epirubicin Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Prestige BioPharma Pte Ltd

                            Singapore arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Prestige BioPharma Pte Ltd

                            Singapore arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trastuzumab,Docetaxel,Epirubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Prestige Biopharma's Herceptin Biosimilar Tuznue® Receives Positive CHMP Opinion

                            Details : Tuznue (trastuzumab-biosimilar) is a HER2/neu receptor antagonist, which is indicatedfor the treatment of HER2 overexpressing breast cancer & metastatic gastric adenocarcinoma.

                            Product Name : Tuznue

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            July 31, 2024

                            Lead Product(s) : Trastuzumab,Docetaxel,Epirubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Peking University

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Peking University

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epirubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : CSPC Ouyi Pharmaceutical Co., Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effectiveness of Cryotherapy Combined With Compression Therapy for Preventing Chemotherapy-induced Peripheral ...

                            Details : Epirubicin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 22, 2022

                            Lead Product(s) : Epirubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : CSPC Ouyi Pharmaceutical Co., Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Prestige BioPharma Pte Ltd

                            Singapore arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Prestige BioPharma Pte Ltd

                            Singapore arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trastuzumab,Docetaxel,Epirubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Result of the Phase 3 Study for Prestige BioPharma’s Herceptin Biosimilar, HD201(Tuznue®), Published in...

                            Details : The study met its primary endpoint (tpCR) and showed equivalent efficacy and comparable safety profile for Troika (HD201), a biosimilar to Herceptin® (trastuzumab), for the treatment of HER2 positive breast and metastatic gastric cancer.

                            Product Name : Tuznue

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 14, 2022

                            Lead Product(s) : Trastuzumab,Docetaxel,Epirubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lund University Hospital

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Lund University Hospital

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epirubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Swedish Breast Cancer Group | Danish Breast Cancer Cooperative Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

                            Details : Epirubicin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 06, 2020

                            Lead Product(s) : Epirubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Swedish Breast Cancer Group | Danish Breast Cancer Cooperative Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Henan Cancer Hospital

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Henan Cancer Hospital

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epirubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Jiangsu Hengrui Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer

                            Details : Epirubicin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Small Cell Lung Carcinoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 27, 2018

                            Lead Product(s) : Epirubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Jiangsu Hengrui Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Fudan University

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Fudan University

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epirubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : Shanghai Zhongshan Hospital | Johnson & Johnson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation

                            Details : Epirubicin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Carcinoma, Hepatocellular.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 16, 2015

                            Lead Product(s) : Epirubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : Shanghai Zhongshan Hospital | Johnson & Johnson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            West German Study Group

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            West German Study Group

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epirubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : AGO Germany

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

                            Details : Epirubicin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 15, 2014

                            Lead Product(s) : Epirubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : AGO Germany

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            OHSU Knight Cancer Institute

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            OHSU Knight Cancer Institute

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epirubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Bayer AG | Oregon Health and Science University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Ri...

                            Details : Epirubicin HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhabdomyosarcoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 31, 2014

                            Lead Product(s) : Epirubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Bayer AG | Oregon Health and Science University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Australasian Gastro-Intestinal Trials Group

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Australasian Gastro-Intestinal Trials Group

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epirubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : National Health and Medical Research Council, Australia | Trans Tasman Radiation Oncology Group | European Organisation for Research and Treatment of Cancer | NCIC Clinical Trials Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma

                            Details : Epirubicin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Stomach Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 19, 2013

                            Lead Product(s) : Epirubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : National Health and Medical Research Council, Australia | Trans Tasman Radiation Oncology Group | European Organisation for Research and Treatment of Cancer | NCIC Clinical Trials Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            West German Study Group

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            West German Study Group

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epirubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Res...

                            Details : Epirubicin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 30, 2013

                            Lead Product(s) : Epirubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth